Wright State University CORE Scholar

Festival of Research

College of Science and Mathematics

3-18-2023

The Influence of ALS-associated MATR3 Toxicity on Cell Size in the Yeast Model

Rahul Shah

Fawaz Ghouse

Widad El-Zein

Quan Zhong

Shulin Ju

Follow this and additional works at: https://corescholar.libraries.wright.edu/cosm_festival_of_research

Part of the Life Sciences Commons

The Influence of ALS-associated MATR3 Toxicity on Cell Size in the Yeast Model Rahul Shah, Fawaz Ghouse, Widad El-Zein, Quan Zhong, Shulin Ju Department of Biological Sciences, Wright State University, Dayton, OH 45435

Background

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease¹. The pathology of ALS is described as the progressive degeneration of motor neurons that initially leads to atrophy of the voluntary muscles followed by the involuntary muscles^{1,2}. Ultimately, the cause of death is pulmonary distress due to loss of function of the diaphragm². Life expectancy after diagnosis is usually one year, and there are currently no cures or effective treatments for this fatal disease³.


Approximately 90% of all ALS cases are sporadic meaning that the disease is developed randomly, while around 10% of the cases are familial meaning that the disease is passed down within a family 3,4 . Over 30 years, many genes have been identified and linked to the development of familial ALS. One of these genes is MATR3 which codes for Matrin-3, a nuclear matrix protein that binds to DNA and RNA with various roles in the nucleus⁵. Matrin-3 is normally found in the nucleus; however, when the gene is mutated, Matrin-3 is depleted from the nucleus and accumulates in clusters in the cytoplasm⁶. Matrin-3 associated toxicity is hypothesized to be either due to the loss of function of the protein in the nucleus or a gain of toxicity function in the cytoplasm leading to neuronal cell death. Furthermore, with increasing MATR3 toxicity in yeast, an increase in cell size was observed.

Objective

Confirm the increase in cell size when MATR3 is expressed and determine whether the increase in cell size is associated to MATR3 toxicity.


Experimental Design

- 1. Express human MATR3 in yeast
- 2. Quantify an increase in cell size with MATR3 expression
- 3. Identify genetic suppressors of MATR3 toxicity
- 4. Determine whether suppressors have a direct effect on Matrin-3
- 5. Determine whether suppressors revert cell size to wild-type



MATR3 is toxic to yeast








Figure 1.

Spotting assay of control, one copy of MATR3, and two copies of MATR3 strains onto plates containing glucose (gene off) and galactose (gene on). Pictures taken after 3 days of growth.

(Glucose)

MATR3 increases cell size




Figure 2.


(A) Brightfield and fluorescence microscopy of control (n=1124), one copy of MATR3 tagged with Green Fluorescent Protein (GFP) (n=1135), and two copies of MATR3 tagged with GFP (n=1190) after 6 hour induction in galactose. Merged images show Matrin-3 protein presence within the cell. Scale= 2µm. (B) Quantification of cell sizes via CellSens software after 6 hour induction in galactose. **p<0.01.


Suppressors rescue MATR3 toxicity

Protein Name ZC11A Zinc finger CCCH domain-containing protein 11A RPGF4 Rap guanine nucleotide exchange factor 4 H12 Histone 1.2 SRTD1 SERTA domain-containing protein 1 HXC4 Homeobox protein box-C4 VTA1 Vacuolar protein sorting-associated protein VTA1 homolog CCNC Cyclin C Annexin II Franscription factor AP-4 SRTD4 SERTA domain-containing protein 4 PLD1 Phospholipase D1 VSX2 Visual system homeobox 2 PDE4D cAMP-specific 3',5'-cyclic phosphodiesterase 4D RPB7 DNA-directed RNA polymerase II subunit RPB7 **RASA3** Pas GTPase-activating protein 3 SRTD2 SERTA domain-containing protein 2

Figure 3.

(A) Chart of known human suppressor genes with protein names. (B) Spotting assay of one copy of MATR3 (-), wild-type (WT), and one copy of MATR3 with suppressor genes on plates containing glucose (gene off) and galactose (gene on). Pictures taken after three days of growth. (C) Spotting assay of two copies of MATR3 (-), WT, and two copies of MATR3 with suppressor genes on plates containing glucose (gene off) and galactose (gene on). Pictures taken after three days of growth.





2X MATR3	ZC11A			۲	Ş.			•	2
	RPGF4	0	•		*		•	\$	3
	H12		٠	۲			٠	۲	3
	SRTD1		۰	۲	. %		•	۲	« •
	SRTD1	۲		۲	•*		•	۲	:";
	HXC4	•	۲		-		•	۲	3
	VTA1	۲	•	۲	°.	•	•	۲	12
	CCNC	0	•	6	**		۲	•	4
	ANXA2	•	•	۲	\$		•	۲	•
	TFAP4	0	0	-	-	•	0	3	Ху.
	SRTD4	0	0			•		۲	. 18
	PLD1	0	۲	•		0	•	•	
	VSX2								-
	PDE4D						•		*
	RPB7		•	۲			•	١	-
	RASA3	۲	۲	۲	•		۲	۹	!:
	SRTD2	۲	•	۲	۹		۲	۲	4
	-	0	۲	•	-	•	·		
WT 🔍 🔍 🔍 🔍									2
Gene OFF (Glucose)						Gene ON (Galactose)			
									0)


IX MATR3 Matrin-3 **2X MATR3** Matrin-3 PGK

Figure 4. (A) Western blot for one copy of MATR3 (-), wild-type (WT), and one copy of MATR3 with suppressor genes after 6 hour induction in galactose. PGK1 served as the loading control. (B) Western blot for two copies of MATR3 (-), WT, and two copies of MATR3 with suppressor genes after 6 hour induction in galactose. PGK1 served as the loading control. The images are representative of two independent trials.

- of MATR3

- 94-102.
- 6(8), e23882.

We are grateful for the discussions of the JuZhong Lab, support of Wright State University Department of Biological Sciences, and funding from the Dale True Grant.



I have been have been for the first and have

Conclusions

MATR3 is toxic in yeast

Cell size increases when MATR3 is expressed

 Suppressors rescue toxicity with two copies of MATR3, but does not rescue toxicity with one copy of MATR3

 Suppressor have a direct reduction of Matrin-3 with two copies of MATR3, but does not have a reduction of Matrin-3 with one copy

References

1. Charcot, J.M., & Joffroy, A. (1869). Deux cas d'atrophie musculaire progressive: avec lésions de la substance grise et des faisceaux antérolatéraux de la moelle épinière. Arch. Physiol. Norm. Pathol., 2, pp.354-367.

2. Talbott, E., Malek, A., & Lacomis, D. (2016). The epidemiology of amyotrophic lateral sclerosis. Neuroepidemiology, 225-238.

3. Chia, R., Chiò, A., & Traynor, B. (2018). Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. *The Lancet Neurology*, 17(1),

4. Leblond, C.S., Gan-Or, Z., et al. (2016). Replication study of MATR3 in familial and sporadic amyotrophic lateral sclerosis. Neurobiol. Aging 37, 209.e17-209.e21 5. Salton, M., Elkon, R., et al. (2011). Matrin 3 Binds and Stabilizes mRNA. Plos ONE,

6. Zhao M, Kim JR, van Bruggen R, Park J. (2018). RNA-Binding Proteins in Amyotrophic Lateral Sclerosis. Mol Cells, 41(9), 818-829.

Acknowledgements